医学
痴呆
干预(咨询)
缓和医疗
疗养院
家庭照顾者
老年学
随机对照试验
精神科
家庭医学
临终关怀
梅德林
日常生活活动
严重痴呆
生活质量(医疗保健)
家庭成员
物理疗法
照顾负担
家庭冲突
作者
Yara J. Schepen,Maartje S. Klapwijk,Jos W. R. Twisk,Wilco P. Achterberg,Jenny Theodora van der Steen,Hanneke J. A. Smaling
出处
期刊:Palliative Medicine
[SAGE Publishing]
日期:2026-10-15
卷期号:: 2692163261486997-2692163261486997
标识
DOI:10.1177/02692163261486997
摘要
Background: Symptom burden at the end of life in dementia remains high. While Namaste Care may enhance comfort, its effect on symptoms during the last week of life has not been established. Aim: To assess the frequency of symptoms experienced by nursing home residents with dementia during the last week of life, and to evaluate the delivery of Namaste Care Family during the last week of life and its effect on comfort and symptom burden. Design: This mixed-methods study combined quantitative data from a cluster-randomised controlled trial with semi-structured interviews. Symptoms were assessed using the End-of-Life in Dementia (EOLD) Scales – Symptom Management (SM; family perspective) and Comfort Assessment in Dying (CAD; staff perspective). Multilevel analyses examined the effect of the Namaste Care Family programme on symptom burden. Interview data was analysed using a content analysis. Setting/participants: Ten nursing homes implemented the Namaste Care Family programme, while nine provided usual care. During the study, 103 of 231 residents with moderate to advanced dementia died (47 intervention group, 56 control group). Interviews ( N = 32) were conducted with family caregivers, staff and volunteers. Results: Serenity (80%), discomfort (72%), and pain (70%) were most frequently observed. The programme had no significant effect on symptom burden (EOLD-SM −0.14 points, 95% CI −5.25, 4.96, p = 0.96; EOLD-CAD 0.35 points, 95% CI −1.98, 2.68, p = 0.77). Interviews showed difficulties in implementing the programme during the last week of life. Conclusions: Comfort and distressing symptoms were both present at the end-of-life phase with dementia. The Namaste Care Family programme did not influence this. Clinical Trial Registration: This trial was registered with the CCMO Research with human participants (ID 5692/5570).
科研通智能强力驱动
Strongly Powered by AbleSci AI